| Autor: |
TASUKU HIROSHIGE, NAOYUKI OGASAWARA, HISAJI KUMAGAE, KOSUKE UEDA, KATSUAKI CHIKUI, KEI-ICHIRO UEMURA, KIYOAKI NISHIHARA, MAKOTO NAKIRI, MITSUNORI MATSUO, SHIGETAKA SUEKANE, TSUKASA IGAWA |
| Předmět: |
|
| Zdroj: |
In Vivo; May/Jun2023, Vol. 37 Issue 3, p1266-1274, 9p |
| Abstrakt: |
Background/Aim: Sarcopenia is a syndrome characterized by the progressive and generalized loss of skeletal muscle mass and has been reported to be a poor prognostic factor for taxane-treated castration-resistant prostate cancer (CRPC). However, whether sarcopenia affects androgen receptor axis-targeted therapies (ARATs) remains unknown. In the present study, we investigated the association between sarcopenia in CRPC and treatment outcomes of ARATs. Patients and Methods: From January 2015 to September 2022, 127 patients who received ARATs as 1st-line treatment for CRPC at our two hospitals were included in the study. We retrospectively evaluated sarcopenia using computed tomography images and investigated whether sarcopenia affects the progression-free survival (PFS) and overall survival (OS) of patients with CRPC treated with ARATs. Results: Out of 127 patients, 99 were diagnosed with sarcopenia. The PFS of the sarcopenic group administered ARATs was significantly better than that of the non-sarcopenic group. Furthermore, in the multivariate analysis of PFS, sarcopenia was an independent favourable prognostic factor. However, there was no significant difference in the OS between the sarcopenic and non-sarcopenia groups. Conclusion: ARATs could more effectively treat patients with CRPC and sarcopenia than patients with CRPC without sarcopenia. Sarcopenia may positively influence the therapeutic effects of ARATs. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
